Connect with us

Technology

UNION therapeutics announces successful completion of the ADESOS Phase 2b study and presentation of data at the RAVE Conference 2024

Published

on

ADESOS Phase 2b study evaluating orismilast as an oral treatment in 233 patients with moderate-to-severe atopic dermatitis (AD) has successfully completedResults from the ADESOS study have been selected for an oral presentation at the late breaking research sessions at the RAVE Conference 2024Orismilast is a next generation, high potency PDE4 B/D selective inhibitor with reported positive results from a Phase 2b study in psoriasis and Phase 2 study in hidradenitis suppurativa (HS); orismilast is currently being evaluated in an ongoing IIT study in ulcerative colitis (UC)UNION is progressing orismilast to Phase 3 development in AD

HELLERUP, Denmark, June 4, 2024 /PRNewswire/ — UNION therapeutics A/S (UNION), a privately held, clinical stage, pharmaceutical development company focused on immunology, today announces successful completion of the ADESOS Phase 2b, randomized, dose-finding study evaluating orismilast as an oral treatment in 233 patients with moderate-to-severe AD.

Topline results from the ADESOS study have been selected for an oral presentation by the Signatory Investigator, Professor Jonathan Silverberg, MD, PhD, MPH at the late breaking research sessions at Revolutionizing Alopecia Areata, Vitiligo, and Eczema (RAVE) Conference on June 8-10, 2024, in Chicago, United States. It will be the first presentation of data from the ADESOS study.

Presentation details

Presentation: Efficacy and safety of orismilast, a potent PDE4B/D inhibitor, in adults with moderate-to-severe atopic dermatitis: a Phase 2b randomized, double-blind, placebo-controlled clinical trial (ADESOS)

Presenter: Jonathan Silverberg, MD, PhD, MPH, Professor of Dermatology at The George Washington University School of Medicine and Health Sciences and Signatory Investigator for ADESOS

Date and time: Monday June 10, 2024, at 1:30 PM – 4:40 PM CDT.

Jonathan Silverberg, MD, PhD, MPH, Professor of Dermatology at The George Washington University School of Medicine and Health Sciences and Signatory Investigator for ADESOS study, said: 

“AD is one of the most common chronic inflammatory skin diseases worldwide. Innovation in recent years has brought good injectable treatments to patients, but a significant unmet medical need for a safe and effective oral treatment still exists. Orismilast offers the potential for a safe oral treatment with early itch reduction and holds a significant promise as a novel treatment option in AD.”

Kim Kjøller, Co-Chief Executive Officer of UNION therapeutics, adds:

“The results from the ADESOS study with orismilast in atopic dermatitis (AD) follows positive read outs in psoriasis and hidradenitis suppurativa (HS) confirming the potential of orismilast as a safe oral treatment across immunology. We are pleased that the Phase 2b results from the ADESOS study have been selected for an oral presentation at the RAVE Conference in Chicago and look forward to the results being shared and discussed with the leading experts in the field.”

Orismilast is developed as a next-generation, high potency PDE4B/D selective inhibitor targeting first-in-class positions in AD and hidradenitis suppurativa (HS), and best in class in psoriasis. The efficacy and safety profile of orismilast have been evaluated in the previously reported IASOS Phase 2b study in psoriasis and OSIRIS Phase 2 study in HS. Data of these studies has been presented at leading scientific conferences and data is published in peer-reviewed journals, including the Journal of American Academy of Dermatology (JAAD) and the Journal of European Academy of Dermatology and Venerology (JEADV).

UNION has scheduled an End of Phase 2 meeting with the FDA to discuss advancing the orismilast development program into Phase 3 studies in AD.  

About the ADESOS Phase 2b study

The Phase 2b study was a randomized, double-blind, placebo-controlled, parallel-group, dose-finding study to evaluate the efficacy and safety of orismilast in patients with moderate to severe AD. The study included 233 patients who were randomized to three active doses (20mg, 30mg, and 40 mg) of orismilast or placebo administered twice daily. The study was conducted in centers in Europe and in the US.

About orismilast

Orismilast is a next generation, high potency PDE4 inhibitor targeting the PDE4B/D subtypes linked to inflammation, demonstrating potent inhibition of Th1, Th2 and Th17 pathways. It acts early in the inflammation cascade, inducing a broad range of anti-inflammatory effects across multiple cytokines involved in many dermatological and immunological diseases.1) 

UNION is developing orismilast as an oral treatment, based on the well-known safety profile of the PDE4 class, across immunology, initially targeting best-in-class or first-in-class positions in atopic dermatitis (AD), hidradenitis suppurativa (HS), psoriasis and ulcerative colitis (UC).

The FDA has cleared UNION’s Investigational New Drug (IND) application for orismilast and granted Fast Track designation for orismilast for the treatment of moderate to severe AD as well as for the treatment of moderate to severe HS.

About atopic dermatitis

AD is a chronic inflammatory skin disease affecting 2.1-4.9 % of the adult population worldwide and is the most common skin disease among children.2) There were approximately 20 million diagnosed moderate-to-severe adult patients with AD in 2023 in the Seven Major Markets (United States, France, Germany, Italy, Spain, UK, and Japan).3) Disease symptoms are characterized by recurrent eczematous skin lesions and intense itch. AD has a substantial psychosocial impact on patients and relatives.4) During disease flares, approximately 80% of patients may experience disturbed sleep, which may also disrupt the sleep of family members.5) The disease also appears to impact the mood and patients have an increased risk of anxiety and depression.6) 

Sources

1)       Blauvelt A et al., Dermatology and Therapy 2023: Next Generation PDE4 Inhibitors that Selectively Target PDE4B/D Subtypes: A Narrative Review – PubMed (nih.gov) &
Silverberg J.I. et al., JEADV 2022: https://onlinelibrary.wiley.com/doi/10.1111/jdv.18818  &
Warren R.B. et al., JEADV 2022: https://onlinelibrary.wiley.com/doi/10.1111/jdv.18812 

2)       Barbarot S et al,. Allergy 2018: https://pubmed.ncbi.nlm.nih.gov/29319189/  https://pubmed.ncbi.nlm.nih.gov/25925336/

3)       EvaluatePharma 2023

4)       Laughter MR et al., British Journal of Dermatology 2021: https://pubmed.ncbi.nlm.nih.gov/33006135/ 

5)       Eichenfield LF et al., Journal of the American Academy of Dermatology 2014: https://pubmed.ncbi.nlm.nih.gov/24290431/

6)       Drucker AM et al., The Journal of Investigative Dermatology 2017: https://pubmed.ncbi.nlm.nih.gov/27616422/

Contacts

Morten Boesen, Chief Financial Officer, UNION therapeutics A/S
+45 2381 5487
morten.boesen@uniontherapeutics.com

Sarah Toft-Jørgensen, Director of Communications and IR, UNION therapeutics A/S
+45 5385 3044
sarah.toft-joergensen@uniontherapeutics.com

About UNION therapeutics

UNION therapeutics is a privately held, clinical stage, pharmaceutical development company focused on immunology. UNION is headquartered in Hellerup, Denmark, and led by an international team combining biotech entrepreneurs and seasoned pharma executives, with a track record of developing and launching more than fifteen marketed drugs. Read more at www.uniontherapeutics.com 

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/union-therapeutics/r/union-therapeutics-announces-successful-completion-of-the-adesos-phase-2b-study-and-presentation-of-,c3994646

 

View original content:https://www.prnewswire.co.uk/news-releases/union-therapeutics-announces-successful-completion-of-the-adesos-phase-2b-study-and-presentation-of-data-at-the-rave-conference-2024-302162871.html

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Technology

Orange County Register Names Roth Staffing Companies one of the Top Workplaces for 2024

Published

on

By

This year’s recognition marks Roth Staffing’s twelfth time on the prestigious list.

ORANGE, Calif., Dec. 23, 2024 /PRNewswire-PRWeb/ — Roth Staffing Companies has been named as one of the Top Workplaces 2024 by Orange County Register Top Workplaces, making it their twelfth time to receive this honor. Roth Staffing earned its spot in the midsize category.

“Having established our business here in Orange County more than 30 years ago, this recognition holds a special place in our hearts. We’re thrilled and grateful to once again be named a Top Workplace!” – Adam Roth, CEO of Roth Staffing Companies.

This list is based solely on employee feedback gathered through a third-party survey administered by employee engagement technology partner Energage, LLC. The confidential survey uniquely measures the employee experience and its component themes, including employees feeling Respected & Supported, Enabled to Grow, and Empowered to Execute, to name a few.

“Having established our business here in Orange County more than 30 years ago, this recognition holds a special place in our hearts. We’re thrilled and grateful to once again be named a Top Workplace!” shared Adam Roth, CEO of Roth Staffing Companies. “At Roth Staffing, our coworkers take pride in their contributions and are inspired to enjoy the process along the way. It’s their dedication to fulfilling our Purpose, ‘To make life better for the people we serve,’ that has made this achievement possible. Here’s to many more milestones ahead in 2025 and beyond!”

About Roth Staffing
Roth Staffing Companies is one of the largest privately held staffing firms in the United States, operating from more than 100 locations across 20 states and the District of Columbia. Roth Staffing consists of five specialized business lines: Ultimate Staffing Services for administrative and office positions, Ledgent Finance & Accounting,Ledgent Technology, Adams & Martin Group for legal staffing, and About Talent for workforce solutions. 

Roth Staffing Companies, L.P. has locations Arizona: Phoenix; California: Brea, Carlsbad, Century City, Cerritos, Costa Mesa, Fremont, Fresno, Inland Empire, Irvine, La Jolla, Los Angeles, Orange County, Oxnard, Palo Alto, Pasadena, Pleasanton, Roseville, Sacramento, San Diego, San Francisco, San Jose, Torrance, Tustin, Woodland Hills; Colorado: Denver; Connecticut: Hartford, New Haven; Florida: Boca Raton, Clearwater, Fort Lauderdale, Orlando, Tampa, West Palm Beach; Georgia: Atlanta; Massachusetts: Boston; Maryland: Baltimore, Columbia, Frederick, Rockville, Timonium; Michigan: Detroit; Minnesota: Bloomington, Minneapolis; Missouri: St. Louis, Kansas City; North Carolina: Raleigh; New Hampshire: Nashua; New Jersey: Paramus; Nevada: Las Vegas; Oregon: Portland; Texas: Austin, Dallas, Houston, North Houston, San Antonio; Virginia: Arlington; Washington: Wisconsin: Milwaukee. 

About Energage
Energage is a purpose-driven company that helps organizations turn employee feedback into useful business intelligence and credible employer recognition through Top Workplaces. Built on 17 years of culture research and the results from 27 million employees surveyed across more than 70,000 organizations,  Energage delivers the most accurate competitive benchmark available. With access to a unique combination of patented analytic tools and expert guidance, Energage customers lead the competition with an engaged workforce and an opportunity to gain recognition for their people-first approach to culture. For more information or to nominate your organization, visit energage.com or topworkplaces.com.

Media Contact

Samantha Cabot, Roth Staffing Companies, 714-939-8600, scabot@rothstaffing.com, rothstaffing.com 

View original content to download multimedia:https://www.prweb.com/releases/orange-county-register-names-roth-staffing-companies-one-of-the-top-workplaces-for-2024-302337047.html

SOURCE Roth Staffing Companies

Continue Reading

Technology

Trading Technologies achieves high spot in Chartis Buyside Platforms 2024 Rankings

Published

on

By

Firm also earns “strong category leader” status for Energy and Equity Trade Surveillance Solutions in new Chartis Market Quadrants report

CHICAGO, Dec. 23, 2024 /PRNewswire/ — Trading Technologies International, Inc. (TT), a global capital markets technology platform services provider, has earned the number 12 spot in the Chartis Buyside Platforms 2024 ranking of the top 50 providers of buy-side platforms and technology. The report released this month showcases the leading players in financial infrastructure and highlights providers delivering essential services and tools – including trading networks, market data, prime brokerage services and more – to buy-side market participants. The ranking, which Chartis called a testament of the “commitment to delivering exceptional value and innovation” to that community, provides insights into how the companies are shaping the industry with advanced solutions in asset management, risk assessment and operational efficiency.

Separately, in Chartis’ just-released Market Quadrants report, which provides a detailed evaluation of key providers offering advanced surveillance solutions tailored to the unique needs of the energy and equity markets, TT achieved “strong category leader” status for both energy and equity trade surveillance solutions. In both categories, TT received a four-star rank for “Industry Leading Platform Capabilities.” Of particular note, TT earned “industry-leading” four-star rankings across all measures in the equity surveillance category, including analytics and modeling, pre-trade reporting, post-trade reporting, data infrastructure and database management, and data visualization and ease/speed of access capabilities.

TT CEO Keith Todd said: “With a long history of service to the sell side, we have been working diligently to grow our appeal to buy-side market participants, and we’re incredibly honored to have earned in short order a number 12 ranking on a cultivated list of the top 50 service providers in the buy-side sector. It’s a great accomplishment that our broadening of products, asset classes and services available on the TT® platform – including our expansion from futures trade surveillance to a powerful multi-asset offering – are already achieving industry-leading recognition across important measures.”

Handling over 2.5 billion transactions this year, the TT platform connects to more than 100 global exchanges and liquidity venues across a growing number of asset classes. The platform delivers advanced tools for trade execution and order management, market data solutions, analytics, trade surveillance, risk management and infrastructure services to the world’s leading sell-side institutions, buy-side firms and exchanges.

Buy-side participants leverage a wide range of TT tools to meet their trading needs, including a comprehensive suite of advanced execution algorithms, algo design and deployment tools, Autospreader and APIs. Through Abel Noser Solutions, a TT company, market participants employ a wide range of sophisticated transaction cost analysis (TCA) products and services across global equities, foreign exchange, futures, fixed income and options.

In June, the firm launched TT Trade Surveillance, a multi-asset trade surveillance solution combining new multi-asset coverage and dozens of new configurable models to supplement the machine learning-driven models from TT Score, the company’s first-generation trade surveillance platform. TT Trade Surveillance provides enhanced trade surveillance capabilities to a wide range of asset classes, including futures, equities, equity options, fixed income and foreign exchange (FX). The system has also recently added a new, innovative way to identify cross-product manipulation, where users can input correlated instruments directly into the user interface to create a single synthetic instrument, and utilize the machine-learning spoofing models to identify patterns of spoofing activity across multiple order books.

With this recognition, TT has now been honored globally and regionally 14 times this year for the TT platform, trade surveillance capabilities, algorithmic trading solution, TCA tool, execution management system (EMS), order management system (OMS) and market data services.

About Trading Technologies

Trading Technologies (www.tradingtechnologies.com) is a Software-as-a-Service (SaaS) technology platform provider to the global capital markets industry. The company’s award-winning TT® platform connects to the world’s major international exchanges and liquidity venues in listed derivatives alongside a growing number of asset classes, including fixed income, foreign exchange (FX) and cryptocurrencies. The TT platform delivers advanced tools for trade execution and order management, market data solutions, analytics, trade surveillance, risk management, clearing, post-trade allocation and infrastructure services to the world’s leading sell-side institutions, buy-side firms and exchanges. The company’s blue-chip client base includes the Tier 1 banks as well as brokers, money managers, hedge funds, proprietary traders, Commodity Trading Advisors (CTAs), commercial hedgers and risk managers. These firms rely on the TT ecosystem to manage their end-to-end trading operations. In addition, exchanges utilize TT’s technology to deliver innovative solutions to their market participants. TT also strategically partners with technology companies to make their complementary offerings available to Trading Technologies’ global client base through the TT ecosystem.

View original content to download multimedia:https://www.prnewswire.com/news-releases/trading-technologies-achieves-high-spot-in-chartis-buyside-platforms-2024-rankings-302338469.html

SOURCE Trading Technologies

Continue Reading

Technology

Allo Secures $100 Million in Debt Financing to Expand Bitcoin-Backed Lending Platform

Published

on

By

DUBAI, UAE, Dec. 23, 2024 /PRNewswire/ — Allo.xyz, a platform for real-world asset (RWA) tokenization and lending, has successfully secured a $100 million Bitcoin-backed credit facility. This landmark credit facility will further enhance Allo’s BTC-backed lending services, catering to institutional and individual participants eager to engage in the growing crypto lending market.

Bolstering its position in the Bitcoin ecosystem, Allo has staked over 544 BTC (valued at $50M+) through the Babylon Bitcoin Staking Protocol. This positions Allo as a key player in enabling Bitcoin-secured networks, with its BTC staking solution minting the $alloBTC token featured prominently on DeFiLlama

The financing round, facilitated by a consortium of lenders including Greengage and a long-standing US institution, reflects rising demand for Bitcoin-secured lending solutions as Allo continues to bridge traditional finance with blockchain technology. Sean Kiernan, CEO of Greengage, expressed his enthusiasm: “We’re excited to support this much-needed new venture and look forward to seeing great things to come.”

Allo’s growth trajectory is underscored by its inclusion in the Binance Labs and BNB Chain MVB Accelerator program, securing up to $750,000 in investment. Allo is also gearing up to launch its native $RWA cryptocurrency, adding new utility to its ecosystem. Additionally, Allo has also made strides in tokenizing real-world assets, with over $2.2 billion in Total Value Locked (TVL) across various assets on the BNB Chain. Allo’s innovative onchain RWA fund solution allows anyone to create funds in under 60 seconds, opening new opportunities for asset management.

Addressing the $900 trillion real-world asset opportunity, Allo continues to pioneer tokenization solutions that seamlessly integrate traditional and digital finance. The company has also secured a $50 million term sheet for lending against SpaceX stock, enabling efficient borrowing solutions for private market shareholders.

Allo’s achievements have garnered recognition, including acceptance into the Qatar Financial Center Digital Asset Lab, underscoring the platform’s commitment to regulatory compliance and technological advancement. With strategic partnerships across the ecosystem—including BNB Chain, Binance Labs, Cobo,  Babylon, and Chainlink—Allo is supported by a robust network of industry leaders.

Allo’s experienced team, boasting over 60 years of combined expertise in cryptocurrency and real-world assets, remains dedicated to unlocking new opportunities and driving innovation in the decentralized financial ecosystem.

For more information, visit Allo.xyz.

View original content to download multimedia:https://www.prnewswire.com/news-releases/allo-secures-100-million-in-debt-financing-to-expand-bitcoin-backed-lending-platform-302338117.html

SOURCE Allo

Continue Reading

Trending